Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2011 AL 2025

Current Insights on the Use of Insulin and the Potential Use of Insulin Mimetics in Targeting Insulin Signalling in Alzheimer's Disease

Woodfield A, Gonzales T, Helmerhorst E, Laws S, Newsholme P, Porter T, Verdile G.

Int J Mol Sci. 2022 Dec 13;23(24):15811. doi: 10.3390/ijms232415811.

BACE1 Inhibitors for Alzheimer's Disease: The Past, Present and Any Future?

Bazzari FH, Bazzari AH.

Molecules. 2022 Dec 12;27(24):8823. doi: 10.3390/molecules27248823.

Phytochemical Compounds and Nanoparticles as Phytochemical Delivery Systems for Alzheimer's Disease Management

Bakrim S, Aboulaghras S, El Menyiy N, El Omari N, Assaggaf H, Lee LH, Montesano D, Gallo M, Zengin G, AlDhaheri Y, Bouyahya A.

Molecules. 2022 Dec 19;27(24):9043. doi: 10.3390/molecules27249043.

Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders

Kaur P, Khera A, Alajangi HK, Sharma A, Jaiswal PK, Singh G, Barnwal RP.

Mol Neurobiol. 2023 Mar;60(3):1690-1720. doi: 10.1007/s12035-022-03164-z. Epub 2022 Dec 23.

The role of adenosine A(2A) receptors in Alzheimer's disease and tauopathies

Launay A, Nebie O, Vijaya Shankara J, Lebouvier T, Buée L, Faivre E, Blum D.

Neuropharmacology. 2023 Mar 15;226:109379. doi: 10.1016/j.neuropharm.2022.109379. Epub 2022 Dec 23.

Role of multi-targeted bioactive natural molecules and their derivatives in the treatment of Alzheimer's disease: an insight into structure-activity relationship

Halder D, Das S, R S J, Joseph A.

J Biomol Struct Dyn. 2023 Dec;41(20):11286-11323. doi: 10.1080/07391102.2022.2158136. Epub 2022 Dec 29.

CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease

Lerner AJ, Arnold SE, Maxfield E, Koenig A, Toth ME, Fortin B, Mast N, Trombetta BA, Denker J, Pieper AA, Tatsuoka C, Raghupathy S, Pikuleva IA.

Alzheimers Res Ther. 2022 Dec 29;14(1):198. doi: 10.1186/s13195-022-01151-z.

Applications of Carbon Dots for the Treatment of Alzheimer's Disease

Guo F, Li Q, Zhang X, Liu Y, Jiang J, Cheng S, Yu S, Zhang X, Liu F, Li Y, Rose G, Zhang H.

Int J Nanomedicine. 2022 Dec 23;17:6621-6638. doi: 10.2147/IJN.S388030. eCollection 2022.

Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies

Imbimbo BP, Ippati S, Watling M, Imbimbo C.

Pharmacol Res. 2023 Jan;187:106631. doi: 10.1016/j.phrs.2022.106631. Epub 2022 Dec 28.

Ginkgolides and bilobalide for treatment of Alzheimer's disease and COVID-19: potential mechanisms of action

Niu TT, Yuan BY, Liu GZ.

Eur Rev Med Pharmacol Sci. 2022 Dec;26(24):9502-9510. doi: 10.26355/eurrev_202212_30702.

Noradrenergic therapies for apathy in Alzheimer's disease?

Husain M.

J Neurol Neurosurg Psychiatry. 2023 Feb;94(2):93. doi: 10.1136/jnnp-2022-330824. Epub 2022 Dec 5.

Multiple approaches for the management of Alzheimer disease: Natural compounds, FDA approved drugs, and nanotechnology interventions

Leena Esam Azhar, Abdulrahman Esam Azhar, Najiah Esam Azhar.

Cell Mol Biol (Noisy-le-grand). 2022 Nov 30;68(11):8-15. doi: 10.14715/cmb/2022.68.11.2.

New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs

Katsenos AP, Davri AS, Simos YV, Nikas IP, Bekiari C, Paschou SA, Peschos D, Konitsiotis S, Vezyraki P, Tsamis KI.

Expert Opin Investig Drugs. 2022 Jan;31(1):105-123. doi: 10.1080/13543784.2022.2022122. Epub 2022 Jan 2.

Effects of Medicare comprehensive medication review on racial/ethnic disparities in nonadherence to statin medications among patients with Alzheimer's Disease: an observational analysis

Browning JA, Tsang CCS, Dong X, Wan JY, Chisholm-Burns MA, Finch CK, Tsao JW, Liu C, Wang J.

BMC Health Serv Res. 2022 Feb 7;22(1):159. doi: 10.1186/s12913-022-07483-8.

AD and its comorbidities: An obstacle to develop a clinically efficient treatment?

Baker J, Schott JM.

Rev Neurol (Paris). 2022 May;178(5):450-459. doi: 10.1016/j.neurol.2022.03.001. Epub 2022 May 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias